Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2024-10-30 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司第三届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangsu Haobo Biomedical Co., Ltd. It details the outcomes of the 13th meeting of the 3rd Supervisory Board, including voting results and decisions to submit certain proposals to the shareholders' meeting. The content focuses on internal governance matters such as exemptions from share lock-up commitments and strategic cooperation agreements, with no financial statements or detailed financial data presented. The document is relatively short (1551 characters) and serves as an official announcement of board meeting resolutions rather than a full report or detailed management discussion. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a proxy solicitation or voting results announcement but rather a board/management information disclosure about supervisory board decisions. Therefore, the best fitting category is Board/Management Information (MANG).
2024-10-30 Chinese
江苏浩欧博生物医药股份有限公司第三届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Jiangsu Haobo Biopharmaceutical Co., Ltd. It details the convening of the board meeting, voting results on various proposals including waivers of share lock-up commitments, approval of a strategic cooperation agreement, and the decision to convene an extraordinary general meeting. The document references related announcements published separately on the Shanghai Stock Exchange website with specific announcement numbers. The content focuses on board decisions and approvals rather than full financial data or detailed reports. The document is relatively short (2508 characters) and serves as a formal disclosure of board meeting resolutions. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2024-10-30 Chinese
江苏浩欧博生物医药股份有限公司关于召开2024年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2024 first extraordinary general meeting of shareholders (临时股东大会) for Jiangsu Haobo Biopharmaceutical Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and instructions for shareholders. It does not contain financial statements or results but is an announcement related to a shareholder meeting. The document length is 3109 characters, which is relatively short and consistent with a meeting notice rather than a full report. There is no indication that this is a report itself, but rather a notification about the meeting and its agenda. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2024-10-30 Chinese
江苏浩欧博生物医药股份有限公司要约收购报告书摘要
M&A Activity Classification · 95% confidence The document is titled as a "要约收购报告书摘要" which translates to "Summary of Tender Offer Report" or "Offer to Purchase Report Summary". It details a partial tender offer by 双润正安信息咨询（北京）有限公司 and its concerted parties to acquire shares of 江苏浩欧博生物医药股份有限公司. The document includes detailed information about the offer price, number of shares to be acquired, the parties involved, legal and regulatory references, and the purpose of the offer. It is a comprehensive disclosure related to a tender offer transaction, including share transfer agreements and financial background of the controlling parties. This type of document corresponds to announcements and documents related to merger proposals or takeover bids. According to the filing definitions, this fits best under the category "M&A Activity" (Code: TAR). The document is substantive and not merely an announcement of a report, so it is not RPA or RNS. Therefore, the classification is TAR with high confidence.
2024-10-30 Chinese
江苏浩欧博生物医药股份有限公司关于控股股东筹划控制权变更事项进展暨股票复牌的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangsu Haoubo Biopharmaceutical Co., Ltd. regarding the progress of a controlling shareholder's planned change of control and the resumption of stock trading. It details the stock suspension and resumption dates, the signing of share transfer agreements, and the need for further approvals and procedures. The document does not contain financial statements or detailed financial data but is a regulatory announcement about corporate control and stock trading status. It fits the category of Capital/Financing Update (CAP) because it relates to changes in control and share transfer activities affecting the company's capital structure and shareholder control.
2024-10-30 Chinese
江苏浩欧博生物医药股份有限公司关于与中国生物制药有限公司等方签订战略合作协议暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a strategic cooperation agreement between Jiangsu Haoyoubo Biopharmaceutical Co., Ltd. and China Biopharmaceutical Co., Ltd. and related parties. It details the framework of the cooperation, the parties involved, the nature of the agreement, and the impact on the company. It also discusses the approval process, including board and shareholder meetings, and the associated risks. The document does not contain financial statements or detailed financial performance data. It is a regulatory announcement about a strategic cooperation agreement and related transactions, including associated shareholder and control changes. It is not a full report like an annual or interim report, nor is it a call transcript or earnings release. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant corporate event that does not fit other specific categories.
2024-10-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.